Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: J Biopharm Stat. 2017 Oct 30;28(2):292–308. doi: 10.1080/10543406.2017.1379532

Figure 1.

Figure 1

Diagram for (a) Biomarker stratified design (BSD), (b) Enriched biomarker stratified design (EBSD) and (c) Auxiliary-variable-enriched biomarker stratified design (AEBSD). For BSD and EBSD, π is the prevalence of biomarker positives in the population; κ1 and κ0 are the selection probability for biomarker positives and biomarker negatives into the randomized cohort, respectively. For AEBSD, π̃ is the prevalence of auxiliary positives in the population; κ̃1 and κ̃0 are the selection probability for auxiliary positives and auxiliary negatives into the randomized cohort, respectively.